Anti-GARP CAR-T: first-in-class therapy for GARP+ cancers
TS-075163 — THE PROBLEM
High-grade gliomas, including glioblastoma multiforme (GBM), are the most common primary central nervous system tumors with a high recurrence rate and extremely poor overall survival with a 5-year survival rate of approximately 5%. Despite success of CAR-T therapy in treating blood canc…
- College: College of Medicine (COM)
- Inventors: Li, Zihai; Velegraki, Maria
- Licensing Officer: He, Panqing